|
|
Article: Phase I trial of CRX-675 initiated in patients with seasonal allergic rhinitis.
- Article from:
- Immunotherapy Weekly
- Article date:
- June 2, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- Corixa Corporation (CRXA), a developer of immunotherapeutics, announced the initiation of a phase I clinical trial to test the safety and immune response activity of CRX-675 for seasonal allergic rhinitis (SAR).
The trial is being conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND). CRX-675 is a member of Corixa's family of proprietary compounds that interact with toll-like receptor 4 (TLR4).
As a TLR4 agonist, CRX-675 may influence innate immunity, the body's first line of defense against a variety of infectious pathogens. TLR4 agonists can ...